drugset / Trial / NCT00045877

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

NCT00045877

Phase 2/3 Completed Chiron Corporation
Treatment

Summary

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Human Interleukin-2 Protein / enzyme biologic
Subject Rituximab Monoclonal antibody

Indications